Compare LTRN & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRN | BMRA |
|---|---|---|
| Founded | 2013 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.5M |
| IPO Year | 2020 | 1995 |
| Metric | LTRN | BMRA |
|---|---|---|
| Price | $0.29 | $1.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | ★ 166.9K | 8.8K |
| Earning Date | 11-17-2026 | 10-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.65 | ★ 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,453,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $1.01 |
| 52 Week High | $4.34 | $2.94 |
| Indicator | LTRN | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 20.94 | 22.63 |
| Support Level | N/A | N/A |
| Resistance Level | $0.84 | $1.75 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 0.07 | 11.54 |
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.